FierceBiotech Feb 18, 2026 Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal
Endpoints News Feb 18, 2026 Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Endpoints News Feb 18, 2026 Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Endpoints News Jan 13, 2026 Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
Endpoints News Jan 12, 2026 Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s